Catalent SG&A Expenses 2012-2024 | CTLT

Catalent sg&a expenses for the twelve months ending June 30, 2024 were $935M, a 12.79% increase year-over-year.

  • Catalent annual sg&a expenses for 2024 were $0.935B, a 12.79% increase from 2023.
  • Catalent annual sg&a expenses for 2023 were $0.829B, a 1.78% decline from 2022.
  • Catalent annual sg&a expenses for 2022 were $0.844B, a 22.85% increase from 2021.

Catalent SG&A Expenses 2012-2024 | CTLT

  • Catalent annual sg&a expenses for 2024 were $0.935B, a 12.79% increase from 2023.
  • Catalent annual sg&a expenses for 2023 were $0.829B, a 1.78% decline from 2022.
  • Catalent annual sg&a expenses for 2022 were $0.844B, a 22.85% increase from 2021.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.8B
Takeda Pharmaceutical (TAK)$43.8B
Merck (MKKGY)$21B
Astellas Pharma (ALPMY)$20.2B
Sandoz Group AG (SDZNY)$19.8B
United Therapeutics (UTHR)$18.3B
Summit Therapeutics (SMMT)$15.8B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12.5B
Madrigal Pharmaceuticals (MDGL)$7.6B
Jazz Pharmaceuticals (JAZZ)$7.6B
Orion OYJ (ORINY)$6.8B
Corcept Therapeutics (CORT)$6.2B
Ionis Pharmaceuticals (IONS)$6.2B
Crinetics Pharmaceuticals (CRNX)$4.9B
PTC Therapeutics (PTCT)$3.4B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.9B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2.2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.9B
Harrow (HROW)$1.9B
Ocular Therapeutix (OCUL)$1.7B
Xencor (XNCR)$1.7B
ARS Pharmaceuticals (SPRY)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
Avadel Pharmaceuticals (AVDL)$1.5B